Mostrar el registro sencillo del ítem

Supervivencia libre de recaída bioquímica en pacientes con cáncer de próstata tratados con radioterapia de intensidad modulada (IMRT) en el Instituto Nacional de Cancerología

dc.contributor.advisorOspino Peña, Rosalbaspa
dc.contributor.authorEsguerra Cantillo, José Alejandro
dc.coverage.spatialMedicinaspa
dc.date.accessioned2015-08-13T14:47:21Z
dc.date.accessioned2019-12-30T19:05:45Z
dc.date.available2015-08-13T14:47:21Z
dc.date.available2019-12-30T19:05:45Z
dc.date.issued2015-02-17
dc.identifier.urihttp://hdl.handle.net/10654/6224
dc.description.abstractObjetivo: Describir los resultados en términos de supervivencia global y supervivencia libre de recaída bioquímica en pacientes con cáncer de próstata que recibieron tratamiento con radioterapia externa técnica de intensidad modulada en el Instituto Nacional de Cancerología, en el periodo del 2008 al 2010. Métodos: estudio de cohorte retrospectivo de pacientes con cáncer de próstata de todos los riesgos, que recibieron tratamiento con radioterapia externa de intensidad modulada (IMRT) en el Instituto Nacional de cancerologia (INC), para evaluar su relación con la supervivencia libre de recaída bioquímica y la supervivencia global. Se empleó el método de Kaplan-Meier para el análisis de supervivencia global y libre de recaída de acuerdo a los niveles de PSA a los 6, 12, 18, 24, 30 y 36 meses post-tratamiento con radioterapia. Resultados: se incluyeron 71 pacientes con cáncer de prostata tratados con IMRT, de los cuales se analizaron 60 pacientes, 15% de bajo riesgo, 26,7% de riesgo intermedio y 58% de riesgo alto. La media de duración de tratamiento fue de 52 días y una dosis media de 73 para bajo riesgo, 74,9 en riesgo intermedio y 77Gy para riesgo alto. La media del PSA post-tratamiento a los 6,12, 18, 24, 30 y 36 meses fue de 0,55ng/dl, 0,48ng/dl, 0,47ng/dl, 0,867 ng/dl y 4,58ng/dl respectivamente. Solo 3 (5%) pacientes presentaron recaida bioquímica post–tratamiento siendo estos de riesgo alto y solo 1 (1,67%) falleció por una causa ajena al cáncer de prostata. Conclusiones: la supervivencia libre de recaída bioquímica y supervivencia global encontradas en este estudio, con esta técnica y con las dosis empleadas nos asegura unos excelentes resultados oncológicos para nuestros pacientes.spa
dc.description.sponsorshipInstituto Nacional de Cancerologíaspa
dc.formatpdfspa
dc.language.isospaspa
dc.publisherUniversidad Militar Nueva Granadaspa
dc.titleSupervivencia libre de recaída bioquímica en pacientes con cáncer de próstata tratados con radioterapia de intensidad modulada (IMRT) en el Instituto Nacional de Cancerologíaspa
dc.typeinfo:eu-repo/semantics/bachelorThesisspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.subject.lembRADIOTERAPIAspa
dc.subject.lembPROSTATA-CANCERspa
dc.publisher.departmentFacultad de Medicinaspa
dc.type.localTrabajo de gradospa
dc.description.abstractenglishObjective: describe the results in terms of overall survival and biochemical relapse-free survival in patients with prostate cancer who were treated with external technical IMRT at the National Cancer Institute in the period from 2008 to 2010. Methods: A retrospective cohort study of patients with prostate cancer all the risks, who were treated with Intensity Modulated Radiation Therapy (IMRT) at the Instituto Nacional de Cancerología to assess their relationship with biochemical relapse-free survival and overall survival. Kaplan-Meier analysis of overall and relapse-free survival according to PSA levels at 6, 12, 18, 24, 30 and 36 months post-radiotherapy was used. Results: 71 patients with prostate cancer treated with IMRT, of which 60 patients, 15% of low risk, 26.7% intermediate risk and 58% high risk were analyzed included. Mean duration of treatment was 52 days and an average dose of 73Gy to low risk, 74,9Gy to intermediate risk and 77Gy to high risk. The mean post-treatment PSA to 6,12, 18, 24, 30 and 36 months was 0,55ng / dl, 0,48ng / dl, 0,47ng / dl, 0.867 ng / dl and 4,58ng / dl respectively. Only 3 (5%) patients had biochemical relapse after treatment these being high risk and only one (1.67%) died of prostate cancer outside the cause. Conclusions: PSA relapse-free survival and overall survival in this study found, with this technique and with the doses used ensures excellent results for our cancer patients.eng
dc.title.translatedOverall survival and biochemical relapse-free survival in patients with prostate cancer treated with intensity modulated radiation therapy (IMRT) at the Instituto Nacional de Cancerología.spa
dc.subject.keywordsProstate Neoplasmsspa
dc.subject.keywordsIntensity Modulated Radiation Therapyspa
dc.subject.keywordsSurvival Analysisspa
dc.subject.keywordsBiochemical Relapse-free Survivalspa
dc.publisher.programOncología Radioterápicaspa
dc.creator.degreenameEspecialista en Oncología Radioterápicaspa
dc.relation.references1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23–47.spa
dc.relation.references2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.spa
dc.relation.references3. Guía de practica clínica para detención temprana, diagnostico, tratamiento, seguimiento y rehabilitación de cáncer de próstata para profesionales de la salud, 2013, guía No. GPC-2013-21, Instituto Nacional de Cancerología E.S.E – Sociedad colombiana de urología.spa
dc.relation.references4. Centers for Disease Control and Prevention. Cancer among men. Available at: http://www.cdc.gov. Accessed February 2, 2012.spa
dc.relation.references5. American Joint Committee on Cancer. Prostate cancer. In: Edge S, Byrd D, Compton C, et al., eds. AJCC cancer staging manual , 7th ed. New York: Springer-Verlag, 2010:525–553.spa
dc.relation.references6. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE et al (1998) Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41:501–510spa
dc.relation.references7. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American college of radiology 95–09. J Clin Oncol 28:1106–1111spa
dc.relation.references8. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67–74spa
dc.relation.references9. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5):277–300.spa
dc.relation.references10. Cooperberg MR, Lubeck DP, Mehta SS, et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003;170(6 Pt 2):S21–S27.spa
dc.relation.references11. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.spa
dc.relation.references12. American Joint Committee on Cancer. Prostate cancer. In: Edge S, Byrd D, Compton C, et al., eds.AJCC cancer staging manual , 7th ed. New York: Springer-Verlag, 2010:525–553.spa
dc.relation.references13. Billis A. Latent carcinoma and atypical lesions of prostate. An autopsy study. Urology1986;28:324–329.spa
dc.relation.references14. Hamstra DA, Bae K, Pilepich MV, et al. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 2011;81(5):1293–1301.spa
dc.relation.references15. Hsing AW, Gao YT, Wu G, et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 2000;60:5111–5116.spa
dc.relation.references16. Barrett-Connor E, Garland C, McPhillips JB, et al. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990; 50:169–173.spa
dc.relation.references17. Woolf CM. An investigation of the familial aspects of carcinoma of the prostate. Cancer1960;13:739–744.spa
dc.relation.referencesCannon L, Bishop D, Skolnick M, et al. Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv 1982;1:47–69spa
dc.relation.references19. Narod SA, Dupont A, Cusan L, et al. The impact of family history on early detection of prostate cancer. Nat Med 1995;1:99–101.spa
dc.relation.references20. Kaul L, Heshmat MY, Kovi J, et al. The role of diet in prostate cancer. Nutr Cancer 1987;9:123–128.spa
dc.relation.referencesSeverson RK, Grove JS, Nomura AM, et al. Body mass and prostatic cancer: a prospective study.BMJ 1988;297:713–715spa
dc.relation.references22. Mettlin C, Selenskas S, Natarajan N, et al. Beta-carotene and animal fats and their relationship to prostate cancer risk. A case-control study. Cancer 1989; 64:605–612.spa
dc.subject.proposalNeoplasias de próstataspa
dc.subject.proposalRadioterapia de intensidad moduladaspa
dc.subject.proposalAnálisis de Supervivenciaspa
dc.subject.proposalSupervivencia libre de recaída bioquímicaspa


Archivos en el ítem

Thumbnail
Nombre:
Informe Final Proyecto de ...
Tamaño:
650.2Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem